Vaccine herd effect

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 9, 2011, Pages 683-689

  Kim, Tae Hyong ^a,b   Johnstone, Jennie ^a,c   Loeb, Mark ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b Soonchunhyang University   (South Korea)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Vaccine herd effect; Vaccine herd immunity

Indexed keywords

INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; PENICILLIN G; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; WART VIRUS VACCINE;

ANTIBIOTIC RESISTANCE; DRUG EFFICACY; EPIDEMIC MENINGITIS; GASTROENTERITIS; HAEMOPHILUS INFLUENZAE TYPE B; HERD IMMUNITY; HUMAN; INFECTION CONTROL; INFLUENZA VACCINATION; PAPILLOMAVIRUS INFECTION; PERTUSSIS; PNEUMOCOCCAL INFECTION; REVIEW; VACCINATION;

HUMANS; IMMUNITY, HERD; VACCINES;

EID: 80051827245     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.582247     Document Type: Review

References (58)

1. Halloran ME, Haber M, Longini IM Jr, Struchiner CJ. Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 1991;133:323-31.
2. Lane JM. Mass vaccination and surveillance/containment in the eradication of smallpox. Curr Topics Microbiol Immunol 2006;304:17-29. (Pubitemid 47413301)
3. Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, et al. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin Infect Dis 2008;46:1-13. (Pubitemid 351263552)
4. Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006;25:494-501. (Pubitemid 43863358)
5. Peltola H, Aavitsland P, Hansen KG, Jonsdottir KE, Nokleby H, Romanus V. A five-country analysis of the impact of four different Haemophilus influenzae type b conjugates and vacci nation strategies in Scandinavia. J Infect Dis 1999;179:223-9. (Pubitemid 29028359)
6. Taranger J, Trollfors B, Bergfors E, Knutsson N, Sundh V, Lagergård T, et al. Mass vaccination of children with pertussis toxoid - decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 2001;33:1004-9. (Pubitemid 32907102)
7. Ntezayabo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003;22:22-7. (Pubitemid 36091773)
8. Güris D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999;28:1230-7. (Pubitemid 29272795)
9. Águas R, Gonçalves G, Gomes MG. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect Dis 2006;6:112-7. (Pubitemid 43138909)
10. Hewlett EL, Edwards KM. Pertussis - not just for kids. N Engl J Med 2005;352:1215-22.
11. Centers for Disease Control and Prevention. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:1-64.
12. th ed. Canada: Public Health Agency; 2006. Available at: http://www.phac-aspc.gc.ca/publicat/cig-gci/index-eng.php (accessed 24 February 2011).
13. De Greeff SC, Mooi FR, Westerhof A, Verbakel JM, Peeters MF, Heuvelman CJ, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 2010;50:1339-45.
14. Ward JI, Cherry JD, Chang SJ, Partridge S, Lee H, Treanor J, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005;353:1555-63. (Pubitemid 41434634)
15. Kretsinger K, Broder KR, Cortese MM, Joyce MP, Ortega-Sanchez I, Lee GM, et al. Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices, Healthcare Infection Control Practices Advisory Committee. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006;55(RR-17):1-37.
16. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009;30:189-209.
17. Smit P, Oherholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977;238:2613-6. (Pubitemid 8274516)
18. World Health Organization. 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008;83:373-84.
19. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; (1): CD000422.
20. Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. Can Med Assoc J 2009;180:48-58.
21. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of proteinpolysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-46.
22. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006;354:1455-63.
23. Harboe ZB, Benfield TL, Valentiner-Branth P, Hjuler T, Lambertsen L, Kaltoft M et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin Infect Dis 2010;50:329-37.
24. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-86. (Pubitemid 36068705)
25. Glezen W P. Emerging infections: pandemic influenza. Epidemiol Rev 1996;18:64-76. (Pubitemid 26303555)
26. Jefferson T, Smith S, Demicheli V, Harnden A, Rivetti A, Di Pietrantonj C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 2005;365:773-80. (Pubitemid 40311364)
27. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 2005;366:1165-74. (Pubitemid 41393594)
28. Agarwal S, Busse PJ. Innate and adaptive immunosenescence. Ann Allergy Asthma Immunol 2010;104:183-90.
29. Desai A, Grolleau-Julius A, Yung R. Leukocyte function in the aging immune system. J Leukoc Biol 2010;87:1001-9.
30. Monto AS, Davenport FM, Napier JA, Francis Jr T. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J Infect Dis 1970;122:16-25.
31. Hurwitz ES, Haber M, Chang A, Shope T, Teo S, Ginsberg M, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 2000;284:1677-82.
32. Loeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJ, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010;303:943-50.
33. Salo H, Kilpi T, Sintonen H, Linna M, Peltola V, Heikkinen T. Cost-effectiveness of influenza vaccination of healthy children. Vaccine 2006;24:4934-41. (Pubitemid 43782683)
34. Talbot TR, Babcock H, Caplan AL, Cotton D, Maragakis LL, Poland GA, et al. Revised SHEA Position Paper: influenza vaccination of healthcare personnel. Infect Control Hosp Epidemiol 2010;31:987-95.
35. Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who work with the elderly. Cochrane Database Syst Rev 2010; (2): CD005187.
36. van den Dool C, Bonten MJ, Hak E, Heijne CM, Wallinga J. The effects of influenza vaccination of health care workers in nursing homes: insights from a mathematical model. PLoS Med 2008;5:1453-60.
37. Bjune G, Hoiby EA, Grønnesby JK. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
38. Bovre K, Gedde-Dahl T W. Epidemiological patterns of meningococcal disease in Norway, 1975-1979. NIPH Ann 1980;3:9-22.
39. Poolman JT, Lind I, Jónsdóttir K, Frøholm LO, Jones DM, Zanen HC. Meningococcal serotypes and serogroup B disease in north-west Europe. Lancet 1986;2:555-8.
40. Ramsay ME, Andrews NJ, Trotter CL. Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003;326:365-6. (Pubitemid 36241472)
41. Maiden MC, Stuart JM. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002;359:1829-30. (Pubitemid 34607060)
42. Caugant DA, Tzanakaki G, Kriz P. Lessons from meningococcal carriage studies. FEMS Microbiol Rev 2007;31:52-63. (Pubitemid 46058820)
43. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54(RR-7):1-21.
44. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010;50:184-91.
45. Parashar UD, Burton A, Lanata C, Boschi-Pinto C, Shibuya K, Steele D, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009;200(Suppl 1):S9-15.
46. Velazquez FR, Matson DO, Calva JJ, Guerrero ML, Morrow AL, Carter-Cambell S, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996;335:1022-8. (Pubitemid 26338732)
47. Vesikari T, Matson DO, Dennehy P. Van Damme P, Santosham M, Rodriguez Z, et al. Rotavirus Efficacy and Safety Trial (REST) Study Team. Safety and efficacy of a pentavalent human - bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33. (Pubitemid 43048948)
48. Clark HF, Lawley D, Mallette LA, DiNubile MJ, Hodinka RL. Decline in cases of rotavirus gastroenteritis presenting to The Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol 2009;16:382-6.
49. Effelterre TV, Soriano-Gabarros M, Debrus S, Newbern EC, Gray J. A mathematical model of the indirect effects of rotavirus vaccination. Epidemiol Infect 2010;138:884-97.
50. Orozco M, Vasquez J, Pedreira C, De Oliveira LH, Amador JJ, Malespin O, et al. Uptake of rotavirus vaccine and national trends of acute gastroenteritis among children in Nicaragua. J Infect Dis 2009;200(Suppl 1):S125-30.
51. World Health Organization. Meeting of the immunization Strategic Advisory Group of Experts, April 2009. Conclusions and recommendations. Wkly Epidemiol Rec 2009;84:220-35.
52. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, et al.; IARC HPV Prevalence Surveys Study Group. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991-8. (Pubitemid 41323035)
53. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-9. (Pubitemid 46962343)
54. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
55. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet 2009;374:301-14.
56. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. Can Med Assoc J 2007;177:469-79. (Pubitemid 47359770)
57. Malmqvist E, Helgesson G, Lehtinen J, Natunen K, Lehtinen M. The ethics of implementing human papillomavirus vaccination in developed countries. Med Health Care Philos 2010;14:19-27.
58. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006;28:88-100. (Pubitemid 44289092)